John Joseph Johnston
Known title: DirectorCIK: 0001874850
Associated companies
Transaction History
| MXCT | ▲ Buy | Grant | 30,421 | $0 | 6/17/2026 | View on chart |
| MXCT | ▲ Buy | Grant | 29,210 | $0 | 6/18/2025 | View on chart |
| MXCT | ▼ Sell | Open Market | 3,000 | $14K | 1/27/2025 | View on chart |
| MXCT | ▲ Buy | Option Exercise | 3,000 | $9K | 1/27/2025 | View on chart |
| MXCT | ▲ Buy | Option Exercise | 3,000 | $9K | 12/26/2024 | View on chart |
| MXCT | ▼ Sell | Open Market | 3,000 | $12K | 12/26/2024 | View on chart |
| MXCT | ▲ Buy | Option Exercise | 891 | $3K | 12/9/2024 | View on chart |
| MXCT | ▲ Buy | Option Exercise | 1,121 | $2K | 12/9/2024 | View on chart |
| MXCT | ▲ Buy | Option Exercise | 483 | $1K | 12/9/2024 | View on chart |
| MXCT | ▼ Sell | Open Market | 2,495 | $9K | 12/9/2024 | View on chart |
| MXCT | ▲ Buy | Option Exercise | 505 | $1K | 12/6/2024 | View on chart |
| MXCT | ▼ Sell | Open Market | 505 | $2K | 12/6/2024 | View on chart |
| MXCT | ▲ Buy | Option Exercise | 3,000 | $9K | 10/28/2024 | View on chart |
| MXCT | ▼ Sell | Open Market | 3,000 | $11K | 10/28/2024 | View on chart |
| MXCT | ▲ Buy | Option Exercise | 3,000 | $9K | 9/26/2024 | View on chart |
| MXCT | ▼ Sell | Open Market | 3,000 | $11K | 9/26/2024 | View on chart |
| MXCT | ▲ Buy | Option Exercise | 3,000 | $9K | 8/26/2024 | View on chart |
| MXCT | ▼ Sell | Open Market | 3,000 | $13K | 8/26/2024 | View on chart |
| MXCT | ▲ Buy | Option Exercise | 3,000 | $9K | 7/26/2024 | View on chart |
| MXCT | ▼ Sell | Open Market | 3,000 | $14K | 7/26/2024 | View on chart |
| MXCT | ▲ Buy | Option Exercise | 5,044 | $8K | 6/27/2024 | View on chart |
| MXCT | ▲ Buy | Option Exercise | 4,956 | $15K | 6/27/2024 | View on chart |
| MXCT | ▼ Sell | Open Market | 10,000 | $40K | 6/27/2024 | View on chart |
| MXCT | ▲ Buy | Grant | 21,367 | $0 | 6/11/2024 | View on chart |
| MXCT | ▼ Sell | Open Market | 5,000 | $22K | 3/26/2024 | View on chart |
| MXCT | ▲ Buy | Option Exercise | 5,000 | $11K | 3/26/2024 | View on chart |
| MXCT | ▲ Buy | Option Exercise | 5,000 | $11K | 2/26/2024 | View on chart |
| MXCT | ▼ Sell | Open Market | 5,000 | $23K | 2/26/2024 | View on chart |
| MXCT | ▲ Buy | Option Exercise | 5,000 | $11K | 1/26/2024 | View on chart |
| MXCT | ▼ Sell | Open Market | 5,000 | $26K | 1/26/2024 | View on chart |
| MXCT | ▼ Sell | Open Market | 5,000 | $23K | 12/26/2023 | View on chart |
| MXCT | ▲ Buy | Option Exercise | 5,000 | $11K | 12/26/2023 | View on chart |
| MXCT | ▲ Buy | Option Exercise | 5,000 | $11K | 11/27/2023 | View on chart |
| MXCT | ▼ Sell | Open Market | 5,000 | $23K | 11/27/2023 | View on chart |
| MXCT | ▲ Buy | Option Exercise | 8,717 | $14K | 11/14/2023 | View on chart |
| MXCT | ▲ Buy | Option Exercise | 1,283 | $3K | 11/14/2023 | View on chart |
| MXCT | ▼ Sell | Open Market | 10,000 | $37K | 11/14/2023 | View on chart |
| MXCT | ▲ Buy | Option Exercise | 2,841 | $5K | 8/30/2023 | View on chart |
| MXCT | ▼ Sell | Open Market | 2,841 | $11K | 8/30/2023 | View on chart |
| MXCT | ▲ Buy | Option Exercise | 2,059 | $3K | 8/29/2023 | View on chart |
| MXCT | ▼ Sell | Open Market | 2,059 | $8K | 8/29/2023 | View on chart |
| MXCT | ▲ Buy | Option Exercise | 100 | $164 | 8/28/2023 | View on chart |
| MXCT | ▼ Sell | Open Market | 100 | $370 | 8/28/2023 | View on chart |
| MXCT | ▲ Buy | Option Exercise | 5,000 | $8K | 7/26/2023 | View on chart |
| MXCT | ▼ Sell | Open Market | 5,000 | $24K | 7/26/2023 | View on chart |
| MXCT | ▲ Buy | Option Exercise | 7,471 | $12K | 6/27/2023 | View on chart |
| MXCT | ▼ Sell | Open Market | 7,471 | $33K | 6/27/2023 | View on chart |
| MXCT | ▲ Buy | Option Exercise | 6,817 | $7K | 6/26/2023 | View on chart |
| MXCT | ▲ Buy | Option Exercise | 712 | $1K | 6/26/2023 | View on chart |
| MXCT | ▼ Sell | Open Market | 7,529 | $34K | 6/26/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
MaxCyte Appoints New Chief Corporate Development Officer
MaxCyte has named Sidharth Kapileshwar as its new Chief Corporate Development Officer. This leadership addition focuses on corporate strategy and growth initiatives. The stock is currently trading near its 52-week low, with an average analyst target of $4.11.
MaxCyte Appoints New Chief Corporate Development Officer. MaxCyte has named Sidharth Kapileshwar as its new Chief Corporate Development Officer. This leadership addition focuses on corporate strategy and growth initiatives. The stock is currently trading near its 52-week low, with an average analyst target of $4.11.